Tocilizumab
Toclizumab is recombinant humanized Anti human Interleukin 6 (IL-6) Receptor monocolonal antibody of the immunoglobulin IgG1k( Gamma 1,Kappa) with a typical polypeptide structure. Toclizumab binds specifically to both soluble and membrane bound IL-6 receptors , and inhibit IL-6 mediated signalling through these receptors, thereby reducing the inflammootry processes in patients with rhematoid arthritis and systemic juvenile rhematoid idiopathic arthritis
Primary Characteristics
Molecular Weight: 148 · Non-proprietary name: Toclizumab · pH: 6.5.
Pharmacokinetics
Distribution: Tocilizumab has a volume of distribution is 3.5 L.
Elimination: it is metabolised via hepatic, plasma half-life is 11-13 days.
Advertisement
Indications
Tocilizumab is primarily indicated in conditions like Juvenile rheumatoid arthritis, Rheumatoid arthritis.
Contraindications
Tocilizumab is contraindicated in conditions like Hepatic impairment, Hypersensitivity to the drug.
Dosage
Tocilizumab's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 6 mg/kg | 6 mg/kg | — | IV infusion | it is administered every 4 week |
| Paediatric Dosage (20kg) | ||||
| 10 mg/kg | 10 mg/kg | — | iv infusion | it is administered every 2 week |
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Tocilizumab produces potentially life-threatening effects which include Anaphylaxis . Careful monitoring is needed with proper medical management.
Tocilizumab is known to cause more or less tolerable side effects which are usually transient. These include Headache, Hypertension , Nasopharyngitis, Respiratory tract infections.
Warnings / Precautions
Interference in Pathology
Tocilizumab may interfere in the diagnosis of Decreases ESR, Increase Haemoglobin.
Available Brands
None recorded.